Latuda: “Procognitive” or Pro-Profit? [Subscribers Only]

Lurasidone (Latuda) was approved by the FDA for schizophrenia in October 2010 and is the 10th atypical antipsychotic in our toolbox. The key question is: does lurasidone have any advantages over existing agents, or is it just another “me-too” drug?

Current Subscribers

Purchase a subscription

To view the full content, you need to purchase a subscription.